dihydroergotamine has been researched along with butorphanol in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (25.00) | 18.7374 |
1990's | 1 (25.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Belgrade, MJ; Ettinger, MG; Ling, LJ; Ruiz, E; Schleevogt, MB | 1 |
Kumar, KL | 1 |
2 review(s) available for dihydroergotamine and butorphanol
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Recent advances in the acute management of migraine and cluster headaches.
Topics: Analgesics; Butorphanol; Capsaicin; Cluster Headache; Dihydroergotamine; Humans; Ketorolac; Metoclopramide; Migraine Disorders; Sumatriptan; Tolmetin | 1994 |
1 trial(s) available for dihydroergotamine and butorphanol
Article | Year |
---|---|
Comparison of single-dose meperidine, butorphanol, and dihydroergotamine in the treatment of vascular headache.
Topics: Adult; Butorphanol; Clinical Trials as Topic; Dihydroergotamine; Drug Therapy, Combination; Female; Humans; Hydroxyzine; Male; Meperidine; Metoclopramide; Morphinans; Vascular Headaches | 1989 |
1 other study(ies) available for dihydroergotamine and butorphanol
Article | Year |
---|---|
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |